Literature DB >> 21085830

Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.

Marcos Abdo Arbex1, Marília de Castro Lima Varella, Hélio Ribeiro de Siqueira, Fernando Augusto Fiúza de Mello.   

Abstract

The main objectives of tuberculosis therapy are to cure the patients and to minimize the possibility of transmission of the bacillus to healthy subjects. Adverse effects of antituberculosis drugs or drug interactions (among antituberculosis drugs or between antituberculosis drugs and other drugs) can make it necessary to modify or discontinue treatment. We briefly review the new guidelines for the pharmacological treatment of tuberculosis, introduced by the Brazilian National Ministry of Health in 2009, and describe the general mechanism of action, absorption, metabolization, and excretion of the first-line drugs used in the basic regimen. We describe adverse drug reactions and interactions (with other drugs, food, and antacids), as well as the most appropriate approach to special situations, such as pregnancy, breastfeeding, liver failure, and kidney failure. We also describe the mechanisms by which the interactions among the antituberculosis drugs used in the basic regimen can cause drug-induced hepatitis, and we discuss the alternatives in this situation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21085830     DOI: 10.1590/s1806-37132010000500016

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  34 in total

1.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

2.  Comment on Wang et al.: One-stage posterior focus debridement, interbody graft using titanium mesh cages, posterior instrumentation and fusion in the surgical treatment of lumbo-sacral spinal tuberculosis in the aged.

Authors:  Haibo Li; Qingyi Dong
Journal:  Int Orthop       Date:  2016-04-25       Impact factor: 3.075

3.  Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Authors:  C Sekaggya-Wiltshire; A von Braun; A U Scherrer; Y C Manabe; A Buzibye; D Muller; B Ledergerber; U Gutteck; N Corti; A Kambugu; P Byakika-Kibwika; M Lamorde; B Castelnuovo; J Fehr; M R Kamya
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

Review 4.  Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Authors:  Mario Regazzi; Anna Cristina Carvalho; Paola Villani; Alberto Matteelli
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

5.  Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.

Authors:  Yun Zhang; Kechun Liu; Hozeifa M Hassan; Hongli Guo; Pingping Ding; Liwen Han; Qiuxia He; Weiyun Chen; Chung-Der Hsiao; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 6.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

7.  Quinolone-isoniazid hybrids: synthesis and preliminary in vitro cytotoxicity and anti-tuberculosis evaluation.

Authors:  Richard M Beteck; Ronnett Seldon; Audrey Jordaan; Digby F Warner; Heinrich C Hoppe; Dustin Laming; Lesetja J Legoabe; Setshaba D Khanye
Journal:  Medchemcomm       Date:  2019-01-11       Impact factor: 3.597

8.  Potential adverse drug events and its predictors among hospitalized patients at medical center in Ethiopia: a prospective observational study.

Authors:  Tamiru Sahilu; Mestawet Getachew; Tsegaye Melaku; Tadesse Sheleme; Duresa Abu; Tesfu Zewdu
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

9.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15

10.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.